Message from the Guest Editors

Dear Colleagues,

Population studies and laboratory data with cells and model organisms indicate that various heat shock proteins play an important role in the genesis and progression of many cancer types. These works led to development of inhibitors of heat shock proteins, some of which have been tested in clinical trials. Since recently we have started understanding the mechanistic aspects of the role of heat shock proteins in cancer, which hopefully will teach us how to rationally combine the inhibitors with other anti-cancer drugs and what types of cancer can be treated with these inhibitors. This issue of Cancers, "Heat shock proteins in cancer: chaperones of tumorigenesis" seeks articles which will shed new light on this topic.

Prof. Dr. Michael Y. Sherman
Dr. Stuart K. Calderwood
Guest Editors
Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 18 days after submission; acceptance to publication is undertaken in 4.1 days (median values for papers published in the first six months of 2018).

Contact us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com
mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI